Literature DB >> 15236578

Refinement of a homology model of the mu-opioid receptor using distance constraints from intrinsic and engineered zinc-binding sites.

Carol B Fowler1, Irina D Pogozheva, Harry LeVine, Henry I Mosberg.   

Abstract

Publication of the rhodopsin X-ray structure has facilitated the development of homology models of other G protein-coupled receptors. However, possible shifts of transmembrane (TM) alpha helices, expected variations in helical distortions, and differences in loop size necessitate experimental verification of these comparative models. To refine a rhodopsin-based homology model of the mu-opioid receptor (MOR), we experimentally determined structural-distance constraints from intrinsic and engineered metal-binding sites in the rat MOR. Investigating the relatively high intrinsic affinity of MOR for Zn(2+) (IC(50) approximately 30microM), we observed that mutation of His(319) (TM7) abolished Zn(2+) inhibition of ligand binding, while mutation of Asp(216) (extracellular loop 2) decreased the effect of Zn(2+), suggesting these residues participate in the intrinsic Zn(2+)-binding center of MOR. To verify the relative orientation of TM5 and TM6 and to examine whether a rhodopsin-like alpha aneurism is present in TM5, we engineered Zn(2+)-binding centers by mutating residues of TM5 and TM6 to Cys or His, making use of the native His(297) in TM6 as an additional Zn(2+)-coordination site. Inhibition of opioid ligand binding by Zn(2+) suggests that residues Ile(234) and Phe(237) in TM5 face the binding-site crevice and form a metal-binding center with His(297) and Val(300) in TM6. This observation is inconsistent with a rhodopsin-like structure, which would locate Ile(234) on the lipid-exposed side of TM5, too distant from other residues making up the Zn(2+)-binding site. Subsequent distance geometry refinement of the MOR model indicates that the rhodopsin-like alpha aneurism is likely absent in TM2 but present in TM5.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15236578     DOI: 10.1021/bi036067r

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  24 in total

1.  Development and in vitro characterization of a novel bifunctional μ-agonist/δ-antagonist opioid tetrapeptide.

Authors:  Lauren C Purington; Katarzyna Sobczyk-Kojiro; Irina D Pogozheva; John R Traynor; Henry I Mosberg
Journal:  ACS Chem Biol       Date:  2011-10-11       Impact factor: 5.100

2.  Interactions of human melanocortin 4 receptor with nonpeptide and peptide agonists.

Authors:  Irina D Pogozheva; Biao-Xin Chai; Andrei L Lomize; Tung M Fong; David H Weinberg; Ravi P Nargund; Michael W Mulholland; Ira Gantz; Henry I Mosberg
Journal:  Biochemistry       Date:  2005-08-30       Impact factor: 3.162

3.  Normal mode analysis suggests a quaternary twist model for the nicotinic receptor gating mechanism.

Authors:  Antoine Taly; Marc Delarue; Thomas Grutter; Michael Nilges; Nicolas Le Novère; Pierre-Jean Corringer; Jean-Pierre Changeux
Journal:  Biophys J       Date:  2005-04-01       Impact factor: 4.033

Review 4.  Homology modeling of opioid receptor-ligand complexes using experimental constraints.

Authors:  Irina D Pogozheva; Magdalena J Przydzial; Henry I Mosberg
Journal:  AAPS J       Date:  2005-10-05       Impact factor: 4.009

5.  Stabilizing effect of Zn2+ in native bovine rhodopsin.

Authors:  Paul S-H Park; K Tanuj Sapra; Michał Koliński; Sławomir Filipek; Krzysztof Palczewski; Daniel J Muller
Journal:  J Biol Chem       Date:  2007-02-15       Impact factor: 5.157

6.  Toward the three-dimensional structure and lysophosphatidic acid binding characteristics of the LPA(4)/p2y(9)/GPR23 receptor: a homology modeling study.

Authors:  Guo Li; Philip D Mosier; Xianjun Fang; Yan Zhang
Journal:  J Mol Graph Model       Date:  2009-04-19       Impact factor: 2.518

7.  Translation of structure-activity relationships from cyclic mixed efficacy opioid peptides to linear analogues.

Authors:  Jessica P Anand; Vanessa R Porter-Barrus; Helen V Waldschmidt; Larisa Yeomans; Irina D Pogozheva; John R Traynor; Henry I Mosberg
Journal:  Biopolymers       Date:  2014-01       Impact factor: 2.505

8.  Pentapeptides displaying mu opioid receptor agonist and delta opioid receptor partial agonist/antagonist properties.

Authors:  Lauren C Purington; Irina D Pogozheva; John R Traynor; Henry I Mosberg
Journal:  J Med Chem       Date:  2009-12-10       Impact factor: 7.446

9.  Modulation of opioid receptor ligand affinity and efficacy using active and inactive state receptor models.

Authors:  Jessica P Anand; Lauren C Purington; Irina D Pogozheva; John R Traynor; Henry I Mosberg
Journal:  Chem Biol Drug Des       Date:  2012-09-12       Impact factor: 2.817

10.  Synthesis and opioid receptor binding affinities of 2-substituted and 3-aminomorphinans: ligands for mu, kappa, and delta opioid receptors.

Authors:  Michael Decker; Yu-Gui Si; Brian I Knapp; Jean M Bidlack; John L Neumeyer
Journal:  J Med Chem       Date:  2010-01-14       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.